Real-world outcomes among patients with metastatic colorectal cancer treated first line with bevacizumab-awwb.

Abstract

e15581 Background: Bevacizumab-awwb (MVASI) was the first FDA-approved biosimilar to Avastin (reference product, RP). Real-world data on effectiveness and safety remain limited and may help address barriers to utilization. Methods: Adult patients who had a confirmed diagnosis of metastatic colorectal cancer (mCRC) (initial presentation on or after 1 January 2018) and initiated bevacizumab-awwb between 19 July 2019 and 30 April 2020 were identified in the ConcertAI Definitive Oncology EMR Dataset. A retrospective medical chart review was conducted to evaluate patient clinical characteristics and outcome data. The current analysis focused on the subset of patients who initiated first-line (1L) bevacizumab-awwb containing therapy (with no prior use of RP) to evaluate incidence of events of interest (EOIs) (Table) and overall survival (OS) probability using Kaplan-Meier analysis. Patients were followed from the initiation of 1L therapy until death, end of record, or end of study period (June 2021), whichever occurred first. Results: A total of 129 patients who initiated bevacizumab-awwb as 1L treatment in combination with chemotherapy were included in this analysis. Majority of patients (78.3%) were treated at clinical oncology practices in a community setting (median age: 60.5 years, 53.5% male). 34.9% of patients had non-metastatic disease (stage of I/II/III) at the initial diagnosis and 38.8% had undergone surgical resection. Median duration of available follow-up data was 10.7 (range: 0.69-22.4) months. During the study period, 100 out of 129 patients had disease progression of which 46 patients had a record of death. The Kaplan-Meier analysis showed that 12-month OS probability was 71.4% (95% CI: 61.0%-79.5%). During treatment with bevacizumab-awwb, 20 EOIs were reported in 18 patients (14.0%). Distribution of events and their management are presented in the Table. None of these EOIs resulted in death. Conclusions: Biosimilar bevacizumab-awwb appeared to be well tolerated, with observed EOIs being manageable, and 12-month OS probability of > 70% for treating patients with mCRC in the real-world setting.[Table: see text]